Who are ANG-3070's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inlyta, lorlatinib plus chemotherapy, Sitravatinib, Vizimpro, Maintenance icotinib, pazopanib or guideline conform chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ang-3070.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ANG-3070 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ANG-3070 (ANG-3070) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Cardiovascular.

phase 2 Tyrosine kinase inhibitor TEK (TIE2 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ANG-3070 (ANG-3070) — Angion Biomedica Corp. ANG-3070 is a tyrosine kinase inhibitor that targets angiopoietin signaling to promote vascular stabilization and tissue repair.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ANG-3070 TARGET	ANG-3070	Angion Biomedica Corp	phase 2	Tyrosine kinase inhibitor	TEK (TIE2 receptor)
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
lorlatinib plus chemotherapy	lorlatinib plus chemotherapy	The First Affiliated Hospital of Guangzhou Medical University	marketed	ALK tyrosine kinase inhibitor (combination therapy)	ALK (anaplastic lymphoma kinase), ROS1
Sitravatinib	sitravatinib	Pfizer	marketed	Tyrosine kinase inhibitor	Tyrosine kinases
Vizimpro	Dacomitinib	Pfizer Inc.	marketed	Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor	Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3
Maintenance icotinib	Maintenance icotinib	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor (TKI)	EGFR (epidermal growth factor receptor)
pazopanib or guideline conform chemotherapy	pazopanib or guideline conform chemotherapy	GWT-TUD GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
Centre Leon Berard · 2 drugs in this class
AB Science · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
Angion Biomedica Corp · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Chang-Ming Huang, Prof. · 1 drug in this class
Deciphera Pharmaceuticals, LLC · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANG-3070 — Competitive Intelligence Brief. https://druglandscape.com/ci/ang-3070. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing